Insulin-like growth factor-1 (IGF-1) levels were analyzed in 43 healthy, nulliparous women aged 19–25 years. Blood samples were drawn in a standardized way in follicular and luteal phases, for present users during cycle days 5–10 and 18–23, respectively. In each women, absolute levels and a difference in p-IGF-1 levels between the two menstrual cycle phases (ΔIGF-1) were related to oral contraceptive (OC) use, height, weight, age, gonadotropin and serum sexual hormone binding globulin (s-SHBG) levels. In the follicular phase and cycle days 5–10, absolute values of p-IGF-1 did not significantly differ between present, former and never users of OCs, in contrast to a significant difference (p = 0.0013) in the luteal phase and cycle days 18–23 between present users and never users, after adjustment for age. ΔIGF-1 was significantly negatively correlated to present OC use, compared with nonusers (p = 0.0002). ΔIGF-1 did not significantly differ between former and never users. While height and weight were not significantly related to ΔIGF-1, there was a significant negative correlation between age and ΔIGF-1 (p = 0.05). Also, s-SHBG and p-IGF-1 were significantly negatively related in the luteal phase and cycle days 18-23 after adjustment for age (p = 0.006), although this relationship disappeared after adjustment for present OC use.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.